Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the combination following anti-PD1/L1 antibody. The study will also provide the opportunity to investigate blood or tumor based factors that may predict response to anti-PD1 antibody in combination with anti-CTLA4. IRB Number 18-004
SponsorsThis trial is sponsored by University of Chicago.
Interested in Clinical Trial?
Providers Associated With This Trial
- Arthur Edward Frankel, M.D.Medical Oncologist and HematologistChief of Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology